In the United States, alteplase may be started prior to patient transfer to a specialty center, whereby endovascular thrombectomy may be attempted. This may lead to alteplase infusion finishing prior to endovascular thrombectomy. However, in the trial, only 23 of 319 patients had their infusion completed prior to thrombectomy. What is the significance of this to the authors? Could this explain the lack of clinical benefit seen between the two groups, despite pretreatment with alteplase leading to successful reperfusion in higher numbers than in the thrombectomy alone group? Thank you!
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.